59 reports of this reaction
4.1% of all COBICISTAT reports
#2 most reported adverse reaction
CUSHING^S SYNDROME is the #2 most commonly reported adverse reaction for COBICISTAT, manufactured by Gilead Sciences, Inc.. There are 59 FDA adverse event reports linking COBICISTAT to CUSHING^S SYNDROME. This represents approximately 4.1% of all 1,443 adverse event reports for this drug.
Patients taking COBICISTAT who experience cushing^s syndrome should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CUSHING^S SYNDROME is moderately reported among COBICISTAT users, representing a notable but not dominant share of adverse events.
In addition to cushing^s syndrome, the following adverse reactions have been reported for COBICISTAT:
The following drugs have also been linked to cushing^s syndrome in FDA adverse event reports:
CUSHING^S SYNDROME has been reported as an adverse event in 59 FDA reports for COBICISTAT. This does not prove causation, but indicates an association observed in post-market surveillance data.
CUSHING^S SYNDROME accounts for approximately 4.1% of all adverse event reports for COBICISTAT, making it one of the most commonly reported side effect.
If you experience cushing^s syndrome while taking COBICISTAT, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.